Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence

Prostate

Volumn 69, Issue 11, 2009, Pages 1206-1221

  Obajimi, Oluwakemi ^a,b   Keen, Judith Clancy ^a,b   Melera, Peter W ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UMDNJ Robert Wood Johnson Medical School at Camden   (United States)

Author keywords

LNCaP; p16; p21; p27; p53; RWPE 1

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; BETA GALACTOSIDASE; GLYCINE; HYPOXANTHINE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PROPIDIUM IODIDE; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PURINE; THYMIDINE; AMP ACTIVATED PROTEIN KINASE KINASE; AMP-ACTIVATED PROTEIN KINASE KINASE; GLUTAMIC ACID DERIVATIVE; PROTEIN KINASE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL AGING; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN LNCAP; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LIQUID SCINTILLATION COUNTING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PURINE SYNTHESIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING; ADENOCARCINOMA; BIOSYNTHESIS; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; EPITHELIUM CELL; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ADENOSINE TRIPHOSPHATE; CELL AGING; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; GLUTAMATES; HUMANS; HYPOXANTHINE; MALE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASES; PURINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650621340     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20971     Document Type: Article

References (57)

1. Davies SP, Carling D, Hardie DG. Tissue distribution of the ampactivated protein-kinase, and lack of activation by cyclic-ampdependent protein-kinase, studied using a specific and sensitive peptide assay. Eur J Biochem 1989;186:123-128.
2. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, Gupta A, Adams JJ, Katsis F, van Denderen B, Jennings IG, Iseli T, Michell BJ, Witters LA. Amp-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003;31:162-168.
3. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000;97:3450-3454.
4. Luo ZJ, Saha AK, Xiang XQ, Ruderman NB.Ampk, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
5. Corton JM, Gillespie JG, Hardie DG. Role of the amp-activated protein-kinase in the cellular stress-response. Curr Biol 1994;4: 315-324.
6. Henin N, Vincent MF, Gruber HE, Vandenberghe G. Inhibition of fatty-acid and cholesterol-synthesis by stimulation of ampactivated protein-kinase. FASEB J 1995;9:541-546.
7. Fujita S, Dreyer HC, Drummond MJ, Glynn EL, Cadenas JG, Yoshizawa F, Volpi E, Rasmussen BB. Nutrient signalling in the regulation of humanmuscle protein synthesis. J Physiol (London) 2007;582:813-823.
8. Wang W, Yang X, Lopez de Silanes I, Carling D, Gorospe M. Increased amp: Atp ratio and amp-activated kinase activity during cellular senescence linked to reduced hur function. J Biol Chem 2003;278:27016-27023.
9. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with aicar, a cell-permeable activator of ampactivated protein-kinase. FEBS Lett 1994;353:33-36.
10. Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate amp-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277:25226-25232.
11. Corton JM, Gillespie JG, Hawley SA. Hardie DG: 5-aminoimidazole-4- carboxamide ribonucleoside - A specific method for activating amp-activated protein-kinase in intact-cells. Eur J Biochem 1995;229:558-565.
12. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kasmatka M, DePinho RA, Cantley LC. The lkb1 tumor suppressor negatively regulates mtor signaling. Cancer Cell 2004;6:91-99.
13. Inoki K, Zhu TQ, Guan KL. Tsc2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-590.
14. Blazquez C, Geelen MJH, Velasco G, Guzman M. The ampactivated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett 2001;489:149-153.
15. IdoY,CarlingD,RudermanN.Hyperglycemia-inducedapoptosis in human umbilical vein endothelial cells - Inhibition by the ampactivated protein kinase activation. Diabetes 2002;51:159-167.
16. Xiang XQ, Saha AK, Wen R, Ruderman NB, Luo ZJ. Ampactivated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004;321:161-167.
17. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Kukidome D, Matsumoto K, Toyonaga T, Asano T, Nishikawa T, Araki E. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005;97:837-844.
18. Saitoh M, Nagai K, Nakagawa K, Yamamura T, Yamamoto S, Nishizaki T. Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of amp-activated protein kinase. Biochem Pharmacol 2004;67: 2005-2011.
19. Li J, Jiang P, Lawrence TS, Sun Y. Ampk-beta 1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis 2003;24:827-834.
20. Kefas BA, Cai Y, Ling Z, Heimberg H, Hue L, Pipeleers D, Van de Casteele M. Amp-activated protein kinase can induce apoptosis of insulin-producing min6 cells through stimulation of c-jun-nterminal kinase. J Mol Endocrinol 2003;30:151-161.
21. Meisse D, Van de Casteele M, Beauloye C, Hainault I, Kefas BA, Rider MH, Foufelle F, Hue L. Sustained activation of ampactivated protein kinase induces c-jun n-terminal kinase activation and apoptosis in liver cells. FEBS Lett 2002;526:38-42.
22. Motoshima H, Goldstein BJ, Igata M, Araki E. Ampk and cell proliferation - Ampk as a therapeutic target for atherosclerosis and cancer. J Physiol (London) 2006;574:63-71.
23. Boritzki TJ, Barlett CA, Zhang C, Howland EE, Margosiak SA, Palmer CL, RominesWH,Jackson RC. Ag2034:Anovel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 1996;14:295-303.
24. Obajimi O, Melera P. The depletion of cellular atp by ag2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells. Cancer Chemother Pharmacol 2008;62:215-226.
25. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. Lncap model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
26. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18:1215-1223.
27. Thomas M, Massimi P, Banks L. Hpv-18 e6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Oncogene 1996;13:471-480.
28. Frippiat C, Chen QM, Zdanov S, Magalhaes JP, Remacle J, Toussaint O. Subcytotoxic h2o2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts. J Biol Chem 2001;276:2531-2537.
29. Pizzorno G, Moroson BA, Cashmore AR, Russello O, Mayer JR, Galivan J, Bunni MA, Priest DG, Beardsley GP. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia ccrf-cem. Cancer Res 1995;55:566-573.
30. King ME, Honeysett JM, Howell SB. Regulation of denovo purine synthesis in human-bone marrow mononuclear-cells by hypoxanthine. J Clin Invest 1983;72:965-970.
31. Hardie DG, Hawley SA, Scott J. Amp-activated protein kinase - Development of the energy sensor concept. J Physiol (London) 2006;574:7-15.
32. Jones RG, Plas DR, Kubek S, Buzzai M,MuJ, Xu Y, Birnbaum MJ, Thompson CB. Amp-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005;18:283-293.
33. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (ink4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996;93:13742-13747.
34. Park C, Lee I, Kang WK. Influence of small interfering rna corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis. Mol Cancer Ther 2006;5:3191-3196.
35. Wagner M, Hampel B, Hütter E, Pfister G, Krek W, Zwerschke W, Jansen-Dürr P. Metabolic stabilization of p27 in senescent fibroblasts correlates with reduced expression of the f-box protein skp2. Exp Gerontol 2001;37:41-55.
36. Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008;9:378-390.
37. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes memorial lecture. Cancer Res 1983;43:3466-3492.
38. Natsumeda Y, Ikegami T, Olah E, Weber G. Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells. Cancer Res 1989;49:88-92.
39. Zhang CC, Boritzki TJ, Jackson RC. An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional g1 checkpoint. Cancer Chemother Pharmacol 1998;41:223-228.
40. Bronder JL, Moran RG. Antifolates targeting purine synthesis allow entry of tumor cells into s phase regardless of p53 function. Cancer Res 2002;62:5236-5241.
41. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (pc-3). Invest Urol 1979;17:16-23.
42. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (du 145). Int J Cancer 1978;21:274-281.
43. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997;18:1225-1231.
44. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-CalacaW, Williams DE.Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001;47:1-13.
45. Bronder JL, Moran RG. A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem 2003;278:48861-48871.
46. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998;35:285-296.
47. Shaw RJ. Lkb1: Cancer, polarity, metabolism, and now fertility. Biochem J 2008;416:1-14.
48. Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D. Hardie DG: 5′-amp activates the amp-activated protein kinase cascade, and ca2+/calmodulin activates the calmodulindependent protein kinase i cascade, via three independent mechanisms. J Biol Chem 1995;270:27186-27196.
49. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, Hardie DG. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for ampactivated protein kinase. Cell Metab 2005;2:9-19.
50. Carling D, Sanders MJ, Woods A. The regulation of ampactivated protein kinase by upstream kinases. Int J Obes 2008; 32:S55-S59.
51. Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR. A p53-dependent s-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci USA 1998;95:14775-14780.
52. Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR, Agarwal ML.Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in s phase in response to starvation for DNA precursors. Proc Natl Acad Sci USA 2006;103:16278-16283.
53. Linke SP, Clarkin KC, DiLeonardo A, Tsou A, Wahl GM. A reversible, p53-dependent g0/g1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996;10:934-947.
54. Taylor WR, Stark GR. Regulation of the g2/m transition by p53. Oncogene 2001;20:1803-1815.
55. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain g2 arrest after DNA damage. Science 1998;282: 1497-1501.
56. Koppelstaetter C, Schratzberger G, Perco P, Hofer J, Mark W, Ollinger R, Oberbauer R, Schwarz C, Mitterbauer C, Kainz A, Karkoszka H, Wiecek A, Mayer B, Mayer G. Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging Cell 2008;7:491-497.
57. Liang J, Shao SH, Xu Z-X, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB. The energy sensing lkb1-ampk pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218-224.